• FY26 was a reset year with a clear path to sustainable growth
• Total revenue was $15.8 billion, down 1%
• Underlying NPATA was $3.1 billion, down 2%
• Dividend maintained; share buy-back program continued

CSL Limited announced its FY2026 results, highlighting a reset year with a clear path to sustainable growth. Total revenue was $15.8 billion, down 1%, and underlying NPATA was $3.1 billion, down 2%. The company reported a net loss after tax of $2.6 billion due to one-off restructuring costs and impairments. CSL's transformation program achieved $176 million in cost savings ahead of target. The company also announced a strategic collaboration with VarmX and plans to invest $1.5 billion in expanding its U.S. plasma manufacturing presence. CSL expects revenue to be in line with the prior year and underlying NPAT growth of approximately 5% in FY27.

FY27: revenue in line with prior year, underlying NPAT growth of approximately 5%

CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business, and targeted investment in commercial capabilities and development programs.